Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan-Feb;25(1):132-136.
doi: 10.4103/aja202223.

Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older

Wei-Hao Shao  1 , Cai-Fang Zheng  1 , Yong-Chao Ge  2 , Xiao-Rui Chen  1 , Bo-Wen Zhang  1 , Gai-Li Wang  1 , Wei-Dong Zhang  1
Affiliations

Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older

Wei-Hao Shao et al. Asian J Androl. 2023 Jan-Feb.

Abstract

A cross-sectional study was conducted to estimate the age-stratified normal levels and age-related changes in the risk predictors of benign prostatic hyperplasia (BPH) progression. A total of 4706 male participants aged 40 years or older in Zhengzhou (China) were enrolled. The values of the International Prostate Symptom Score (IPSS), prostate-specific antigen (PSA), prostate volume (PV), and postvoid residual urine volume (PVR) significantly increased with age. Nonlinear relationships between age and IPSS scores ≥8 (P for nonlinearity = 0.046), PSA level ≥1.6 ng ml-1, PV ≥31 ml, or PVR ≥39 ml (all P for nonlinearity <0.001) were observed. After the age of 61 years, the risk indicators related to BPH progression were positively correlated with age (odds ratio [OR] >1), regardless of the predictors of the IPSS score, PSA level, PV, or PVR; and the OR values increased gradually. Therefore, after the age of 61 years, the risk predictors related to BPH progression were positively correlated with age.

Keywords: aging; lower urinary tract symptoms; postvoid residual urine volume; prostate volume; prostate-specific antigen.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Mean value and 95% CI by age group for (a) IPSS score, (b) PSA level, (c) PV, and (d) PVR. CI: confidence interval; IPSS: International Prostate Symptom Score; PSA: prostate-specific antigen level; PV: prostate volume; PVR: postvoid residual urine volume.
Figure 2
Figure 2
Associations among age and (a) IPSS score ≥8, (b) PSA level ≥1.6 ng ml–1, (c) PV ≥31 ml, and (d) PVR ≥39 ml. Logistic regression models with restricted cubic spline analyses adjusted for marital status, education level, residence, BMI, smoking status, drinking status, and history of hypertension, hyperlipidemia, and diabetes. IPSS: International Prostate Symptom Score; PSA: prostate-specific antigen; PV: prostate volume; PVR: postvoid residual urine volume; OR: odds ratio; CI: confidence interval; BMI: body mass index.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361:1359–67. - PubMed
    1. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003;61:267–73. - PubMed
    1. Wang W, Guo Y, Zhang D, Tian Y, Zhang X. The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys. Sci Rep. 2015;5:13546. - PMC - PubMed
    1. Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016;13:108–19. - PubMed
    1. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14. - PubMed

Substances